Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.35 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 5/20 | 0.34 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.34 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21310317 | 0.84 | GRM2 (0.40) | RORCLTB4RLTB4R2 | |
| SCHEMBL14900588 | 0.81 | RORC (0.39) | RORCMMEL1CXCR3FFAR4LTB4R | |
| SCHEMBL14900465 | 0.78 | RORC (0.40) | RORCMMEL1S1PR2S1PR4MEN1 | |
| SCHEMBL18724747 | 0.73 | FFAR4 (0.39) | FFAR4LTB4RLTB4R2MME | |
| SCHEMBL16939239 | 0.73 | FFAR4 (0.39) | FFAR4LTB4RLTB4R2MME | |
| SCHEMBL18027484 | 0.71 | FFAR4 (0.39) | RORCFFAR4LTB4RLTB4R2MME | |
| SCHEMBL16939237 | 0.70 | CHRM3 (0.36) | FFAR4MME | |
| SCHEMBL10252545 | 0.70 | SMN1; SMN2 (0.38) | MEN1LMNAKMT2AALDH1A1 | |
| SCHEMBL14902419 | 0.69 | MME (0.38) | RORCMMEL1MEN1LMNAKMT2A | |
| SCHEMBL22404869 | 0.69 | FASN (0.35) | MMEL1FFAR4MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10744104-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190262297-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-08-29 | — | — | US | disclosed |
| EP-2964616-B1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744104-B2 | Neprilysin inhibitors | MME, REN, ACE | RORC 4543/4885MMEL1 213/4885CXCR3 4059/4885 |
| US-20190262297-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | RORC 4543/4885MMEL1 213/4885CXCR3 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.